Novartis International AG
Source: Novartis International AG |

Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials

Over the next five years, as part of its commitment, Novartis will invest more than USD 100 million to advance research and development of next-generation treatments to combat emerging resistance to artemisinin and other currently used antimalarials

Company to invest more than USD 100 million to advance research and development of new antimalarials over the next five years Commitment includes expanding access to pediatric antimalarials and implementing capacity-building programs to contribute to the WHO’s target of reducing malaria-related child mortality by at least 90% by 2030 New…

Novartis International AG
Source: Novartis International AG |

Novartis, ASCP and ACS join forces to fight cancer in Ethiopia, Uganda and Tanzania

The objective is to provide patients with rapid cancer diagnostics and appropriate care

First focus will be on Ethiopia, Uganda and Tanzania. Cancer is on the rise in Africa, with more than 500,000 deaths annually. Novartis (www.Novartis.com), the American Society for Clinical Pathology (ASCP) (www.ASCP.org) and the American Cancer Society (ACS) (www.Cancer.org) announced today they will work together to devise a common approach…

Novartis International AG
  • Multimedia content

  • Videos (1)
    • Alvine: living with hypertension in Cameroon
  • Images (5)
    • Harald Nusser, Head of Novartis Social Business, and André Mama Fouda, Honorable Minister of Public Health of the Republic of Cameroon at the signature of the Memorandum of Understanding
    • Alvine, aged 50, was diagnosed with hypertension seven years ago.She had to travel to Bamenda, a city 8 hours away by bus, to buy a treatment she could afford. Today, she travels 5 kilometers from her home to the local hospital to get her treatment and have her health numbers checked.
    • The Etoug-Ebe Baptist Hospital in Yaoundé, the capital city of Cameroon, is run by the Cameroon Baptist Convention Health Services. This is one of the first facilities in which Novartis Access medicines are available to patients to treat conditions such as hypertension.
    • Cordel Ndasi, a nurse at the Etoug-Ebe Baptist Hospital, measures a patient’s blood pressure. She hopes patients will be more motivated to know their status if they know they can have access to affordable medicines. “As a nurse, it pains my heart when I see someone coming in with complications. If this person had been diagnosed earlier, we could have given her a treatment to keep her healthy and productive.”
    • Getting high-quality treatments at an affordable price is an important element of the prevention and control programs put in place by the government of Cameroon to successfully control NCDs. Novartis Access medicines are already available through some Cameroon Baptist Convention facilities and will be extended to other faith-based organizations and ultimately the entire country.
  • Links (4)
  • All (10)
Source: Novartis International AG |

Novartis Access and government of Cameroon sign memorandum of understanding to fight chronic diseases

Cameroon becomes the sixth country to launch Novartis Access

We are pleased to announce that Novartis (NYSE:NVS) (SIX:NOVN) (www.Novartis.com) and the Ministry of Public Health of Cameroon have signed a Memorandum of Understanding to implement Novartis Access in Cameroon (http://SocialBusiness.Novartis.com). The collaboration also includes capacity-building activities with the Cameroon Baptist Convention Health Services (CBCHS) on community awareness. Initially, Novartis…

Novartis International AG
Source: Novartis International AG |

Novartis launches SMS for Life 2.0 in Nigeria to help improve Access to Essential Medicines

The program aims to increase the availability of essential medicines and improve care for patients across the region by using simple, available, and affordable technology

SMS for Life 2.0 launches for the first time in Kaduna State, Nigeria’s third most populous region, in collaboration with the Kaduna State Ministry of Health Program uses smartphones and tablet computers to improve access to medicines and increase disease surveillance, helping to provide better care for patients Initiative builds…

Source: Novartis International AG |

Malaria experts and African leaders challenged to maintain the momentum and win the race for malaria elimination

Novartis convenes the 15th Annual National Malaria Control Program (NMCP) Best Practice Sharing Workshop today in Dakar, Senegal

National Malaria Control Program best practice sharing workshop takes place in Senegal, which has made great strides in malaria control   Event brings together delegates from 33 African countries to accelerate malaria elimination efforts Novartis Malaria Initiative celebrates treatment delivery milestone, with more than 800 million treatments distributed since 2001,…

Source: Novartis International AG |

Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment

Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from MMV in collaboration with the Bill & Melinda Gates Foundation

Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates Foundation KAF156 belongs to a novel class of antimalarials that act against both the blood and liver stages of the parasite’s lifecycle Antimalarials…

Source: Novartis International AG |

300 million child-friendly antimalarial treatments supplied without profit by Novartis

Coartem® Dispersible*, the first WHO prequalified(1) pediatric antimalarial treatment, has become the standard of care in over 30 malaria-endemic countries Since 2009, Novartis has supplied 300 million Coartem® Dispersible treatments without profit, mostly to the public sector, to treat children suffering from malaria Together with other innovations, Coartem® Dispersible contributed to…

Source: Novartis International AG |

Kenya first country to launch ‘Novartis Access’, expanding affordable treatment options against chronic diseases

Novartis Access is a first-of-its-kind portfolio of products aimed at increasing access to medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer in low- and low-middle-income countries

Novartis Access is a first-of-its-kind portfolio of products aimed at increasing access to medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer in low- and low-middle-income countries Program supports Kenyan government on noncommunicable disease (NCD) prevention and control – by 2030, NCDs are expected to cause more than 60%…